Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD)
Proposed studies can include later stage preclinical research (vaccine optimization studies, immunogenicity/challenge studies, etc.), GLP/GMP vaccine production, GLP preclinical toxicology and safety studies, pre-IND/IND preparation and submission, and clinical testing. Preclinical research alone, without clear, feasible, and realistic plans for progressing to human testing within the period of award, will not be accepted. Although it is not a requirement for IPCAVD, investigators are encouraged to discuss clinical evaluation of their candidate vaccines with the NIAID-supported HIV Vaccine Trials Network.
Applicants must delineate in their applications discrete goals with measurable milestones and include criteria to be used in deciding when to proceed to the next phase of product development towards a testable vaccine in humans. Funding of the final 2 years of the grant will be contingent upon the successful completion of negotiated milestones and the feasibility of clinical testing within the funding period as determined by a midpoint grant review. This program will use the NIH multi-project cooperative agreement (U19) mechanism. Under the cooperative agreement, the NIH purpose is to support and/or stimulate the recipient's activity by involvement in and otherwise working jointly with the award recipient in a partner role, but it is not to assume direction, prime responsibility, or a dominant role in the activity. Applicants are strongly encouraged to discuss questions regarding appropriateness of their research for the IPCAVD grant mechanism and/or funding issues with the NIAID/DAIDS Program contact.
IPCAVD Contact Information
Michael Pensiero, Ph.D.
Phone: 301-435-3749
Fax: 301-402-3684
E-mail: mpensiero@niaid.nih.gov
Current Awardees
Mark Feinberg
Optimizing the immunogenicity of MVA-based AIDS vaccine
Emory University
Dan Barouch
Novel adenovirus vector-based vaccines for HIV-1
Beth Israel Deaconess Medical Center
Hildegund Ertl
HIV-1 Vaccine based on chimp serotypes of Adenovirus
Wistar Institute
Harriet Robinson
GM-CSF-adjuvanted Clade C DNA/MVA and MVA/MVA vaccines
Geovax, Inc.
Dan Barouch
Novel heterologous adenovirus prime-boost HIV-1 vaccine
Beth Israel Deaconess Medical Center
back to top